Pure Global AI
NCT06342037Not yet recruiting

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

The Netherlands Cancer InstitutePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Tiragolumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Netherlands Cancer Institute
Timeline & enrollment
Phase
Phase 2
Start date
May 15, 2024
End date
Apr 01, 2030
Enrollment
60 participants
Primary outcome

PFS-12,Incidence of adverse events

Summary

This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study
 the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced
 triple-negative breast cancer.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06342037
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06342037 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Netherlands Cancer Institute and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.